Cardiomyopathy pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 15: Line 15:
</gallery>
</gallery>
</div>
</div>


<div align="left">
<div align="left">
Line 23: Line 22:
</gallery>
</gallery>
</div>
</div>


<div align="left">
<div align="left">
Line 38: Line 36:
</gallery>
</gallery>
</div>
</div>


<div align="left">
<div align="left">
Line 46: Line 43:
</gallery>
</gallery>
</div>
</div>


<div align="left">
<div align="left">
Line 54: Line 50:
</gallery>
</gallery>
</div>
</div>


<div align="left">
<div align="left">
Line 69: Line 64:
</gallery>
</gallery>
</div>
</div>


<div align="left">
<div align="left">
Line 77: Line 71:
</gallery>
</gallery>
</div>
</div>


<div align="left">
<div align="left">
Line 85: Line 78:
</gallery>
</gallery>
</div>
</div>


<div align="left">
<div align="left">
Line 93: Line 85:
</gallery>
</gallery>
</div>
</div>


<div align="left">
<div align="left">
Line 101: Line 92:
</gallery>
</gallery>
</div>
</div>


<div align="left">
<div align="left">
Line 118: Line 108:
</gallery>
</gallery>
</div>
</div>


<div align="left">
<div align="left">
Line 129: Line 118:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
# Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003; 107:2227.
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Revision as of 02:55, 16 December 2018

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Cardiomyopathy pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiomyopathy pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiomyopathy pathophysiology

CDC on Cardiomyopathy pathophysiology

Cardiomyopathy pathophysiology in the news

Blogs on Cardiomyopathy pathophysiology

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Cardiomyopathy pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Pathophysiology

Gross Pathology

Images shown below are courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

Microscopic Pathology

Images shown below are courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

References

  1. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003; 107:2227.

Template:WH Template:WS